Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | How can MRD guide treatment of AML?

Christopher Hourigan • 4 Jun 2022
ASCO 2022
Acute Myeloid Leukemia Leukemia
Pre-Measure

Christopher Hourigan, MD, DPhil, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, reflects on how measurable residual disease (MRD) testing can be used to guide the treatment and management of patients with acute myeloid leukemia (AML). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Christopher Hourigan

1:11
Current role of MRD in AML
Christopher Hourigan • 4 Jun 2022
1:09
Pre-MEASURE: patients with AML in complete remission but high risk of relapse following alloHCT
Christopher Hourigan • 4 Jun 2022
2:50
Conditioning intensity and genomics: relapse after allogeneic transplant in MDS
Christopher Hourigan • 16 Jun 2020
2:34
Proteomic profiling of bone marrow in AML
Christopher Hourigan • 16 Jun 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals